CHEK2 and ductal breast carcinoma in situ: Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 were significantly associated with over two-fold increased risk of DCIS, with BRCA2 mutations conferring the highest risk at nearly five-fold.